Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
What Chinese Consumers Want From Western Retailers(5/23/2018 )  (Premium)
  Written by Deborah Weinswig of CoreSight Research, this Forbes article concludes that "all signs point to sustained demand for imported goods in China ... Therefore, expect more brands and retailers to enter the Chinese market via cross-border e-commerce platforms and for those already selling into China to build out their product offerings to tap this demand."
Industry News
Pivotal bioVenture Partners China Closes Inaugural $150M Early Stage VC Fund(5/25/2018 )  (free)
  Pivotal bioVenture Partners China (Pivotal China), a member of Nan Fung Life Sciences (NLFS) announced on May 25 the closing of Pivotal bioVenture Partners China USD Fund I, raising $150 million to incubate and build Life Sciences companies in China.
Brii Biosciences Announces Significant Partnerships and Financing(5/25/2018 )  (free)
  Brii launches with three foundational and strategic partnerships that will accelerate infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients.
Karyopharm and Antengene Sign Exclusive License Agreement for Chinese and Select Asian Market(5/24/2018 )  (Premium)
  Karyopharm Therapeutics and Antengene announced on May 24 their entry into an exclusive license agreement for the development and commercialization of four of Karyopharm¡¯s novel, oral drug candidates, including selinexor, eltanexor, verdinexor and KPT-9274.
China Approves XiAn Janssen's INVEGA SUSTENNA(5/24/2018 )  (Premium)
  The CNDA has approved XiAn Jassen's INVEGA SUSTENNA (3 month paliperidone palmitate injection) in China, According to a news release by XiAn Jassen. INVEGA SUSTENNA is used for schizoaffective disorder either alone or in combination with other medicines such as mood stabilizers or antidepressants and is used to treat schizophrenia.
WuXi Biologics to Invest to Build a S$80M Manufacturing Facility in Singapore(5/23/2018 )  (free)
  WuXi Biologics announced on May 22 that it is to invest S$80 million (equivalent to approximately US$60 million) and hire approximately 150 employees to establish a state-of-the-art biologics manufacturing facility in Singapore.
A-Share Listed Domestic Pharma Companies Report Q1/2018 Performance(5/23/2018 )  (Premium)
  Among them, nine companies had net profits above CNY 500 million in Q1/2018, compared with only seven in the previous year. Three companies had more than CNY 1 billion in net profits in the same period. On the other hand, Hengrui Medicines had the highest net profit margin in the period at 86.47%.
Pfizer's Chinese Urban Hospital Drug Sales Rebounded in 2017(5/23/2018 )  (Premium)
  Pfizer's drug sales to urban hospitals in major Chinese cities were CNY 5,723 million in 2017 (excluding sales of Pfizer manufacturing businesses in China), up nearly 10% from 8% in the previous year, according to the PDB system of CPIIC.
Takeda Sells Majority Stake in JV Techpool to Chinese Partners(5/22/2018 )  (Premium)
  Takeda Pharmaceutical Co. Ltd. (TSE: 4502) announced on May 21 that it has entered into an agreement to sell its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma Co (Techpool) to Chinese JV partners including Shanghai Pharma, which will become the majority owner thereafter.
Bioasis and WuXi Biologics Enter Strategic Collaboration for Brain Cancer Drug(5/22/2018 )  (Premium)
  BIOASIS TECHNOLOGIES and WUXI BIOLOGICS announced on May 21 an initial strategic collaboration for the development and manufacturing of xB3-001, Bioasis¡¯ lead investigational biological candidate to treat brain cancer.
Salubris Pharma, MedAllliance Enter Investment/Licensing Deal for Novel CVD Therapy(5/22/2018 )  (Premium)
  Salubris will make a $20 mln equity investment in MedAlliance and commit an additional $10 mln in developmental milestones for exclusive rights for latter's Selution, a potential best-in-class sirolimus micro-reservoir drug-coated balloon, for peripheral and cardiovascular applications in China.
Regulatory News
CNDA and NHC issue Joint Announcement for Optimization of Drug Evaluation and Approval(5/23/2018 )  (Premium)
  The CNDA and NHC issued a joint document, Announcement on Matters Concerning Optimization of Drug Registration Evaluation and Approval (2018#23), on May 23. It became effective upon issuance.
CFDA Releases Generic Drug Quality and Efficacy Equivalence Evaluation Announcement (Batch 4)(5/22/2018 )  (Premium)
  The announcement includes essential information on a total of 12 drug products (including atorvastatin tablets) passing the generic drug quality and efficacy evaluation in May 2018 (batch 4).
General Health
Mental Health Issues Rise among Chinese Children(5/25/2018 )  (Premium)
  Mental health specialists warned of rising mental health issues among Chinese children and adolescents including attention-deficit hyperactivity disorder, or ADHD, which now hits roughly 5% of them, according to the China Daily.
MOHRSS Publishes 2017 Human Resources and Social Security Statistical Report, Outlining Essential BMI Information(5/22/2018 )  (Premium)
  The Ministry of Human Resources and Social Security (MOHRSS) published the 2017 Human Resources and Social Security Statistical Report, highlighting essential basic medical insurance system enrollment and financial Information.
Five Chinese Agencies Jointly Issue 1st Batch of Rare Disease List(5/22/2018 )  (Premium)
  Five central government agencies including the NHC, MOST, MIIT, CNDA and SATCM jointly issued on May 22 a new document, the Rare Disease List Batch 1, which contains a total of 121 rare diseases.
China May Scrap Its Two-child Family Planning Policy(5/22/2018 )  (Premium)
  China is considering an end to the limit imposed on the number of children that each family can have, according to Bloomberg. A formal announcement by China's government could be made by the end of this year.
People in the News
Recent Executive Moves(5/25/2018 )  (Premium)
  Recent Chinese pharma executive movements at companies including Galderma, IQVIA and Bayer Healthcare China.
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links